IRIS UniCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.557
NA - Nord America 1.493
AS - Asia 1.197
SA - Sud America 173
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.441
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.467
CN - Cina 511
DE - Germania 384
SG - Singapore 346
IT - Italia 341
SE - Svezia 275
BR - Brasile 158
IN - India 136
IE - Irlanda 130
UA - Ucraina 85
ID - Indonesia 79
FR - Francia 66
GB - Regno Unito 60
FI - Finlandia 54
RU - Federazione Russa 52
KR - Corea 35
AT - Austria 26
TR - Turchia 23
BE - Belgio 19
CA - Canada 18
NL - Olanda 18
JP - Giappone 13
HK - Hong Kong 10
IR - Iran 10
PL - Polonia 9
AR - Argentina 8
CI - Costa d'Avorio 8
ES - Italia 8
PH - Filippine 8
CH - Svizzera 6
EG - Egitto 6
IL - Israele 6
MX - Messico 6
CZ - Repubblica Ceca 5
RO - Romania 5
VN - Vietnam 5
LT - Lituania 4
CL - Cile 3
KZ - Kazakistan 3
ZA - Sudafrica 3
AW - Aruba 2
CO - Colombia 2
GR - Grecia 2
JO - Giordania 2
KG - Kirghizistan 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
HU - Ungheria 1
IQ - Iraq 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
VE - Venezuela 1
Totale 4.441
Salva come PNG Salva come JPEG
Città #
Chandler 278
Singapore 205
Hangzhou 186
Ashburn 154
Dublin 126
Hyderabad 105
Jakarta 78
Rome 72
Wilmington 61
Beijing 60
San Mateo 60
New York 53
Jacksonville 47
Milan 45
Boston 41
Nanjing 41
Moscow 34
Hefei 33
Helsinki 33
Cattolica 31
Seoul 30
Princeton 29
Los Angeles 23
Houston 22
The Dalles 22
Zhengzhou 22
Redwood City 20
Dearborn 18
Brussels 17
Lawrence 17
Fairfield 16
Nanchang 16
Washington 16
Ann Arbor 15
Vienna 15
Bremen 14
Frankfurt am Main 14
Seattle 14
Izmir 13
Düsseldorf 12
Marseille 12
Mountain View 12
Munich 12
Nuremberg 12
São Paulo 12
Woodbridge 12
Bari 10
Boardman 9
Hong Kong 9
Naples 9
Nürnberg 9
Portsmouth 9
Santa Clara 9
Abidjan 8
Andover 8
Busto Arsizio 8
Paris 8
Richardson 8
Guangzhou 7
Hebei 7
Leawood 7
Cairo 6
Cambridge 6
London 6
Portland 6
Redmond 6
Shanghai 6
Belo Horizonte 5
Changsha 5
Council Bluffs 5
Falkenstein 5
Kunming 5
Lauterbourg 5
Mumbai 5
Norwalk 5
Shenyang 5
Tianjin 5
Tokyo 5
Toronto 5
Turin 5
Amsterdam 4
Antalya 4
Betim 4
Chicago 4
Edinburgh 4
Manchester 4
New Haven 4
Newark 4
Palermo 4
Rubano 4
San Francisco 4
São Bernardo do Campo 4
Tel Aviv 4
University Park 4
Asti 3
Augusta 3
Bern 3
Buenos Aires 3
Goiânia 3
Guidonia Montecelio 3
Totale 2.480
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 457
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 317
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 148
Sonographic imaging of urinoma 139
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 135
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 126
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 115
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 109
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 107
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 95
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 92
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 86
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 81
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 75
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 74
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 71
Sonographic imaging of urinoma. 68
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 68
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 64
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 62
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 61
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 58
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 58
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 57
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 57
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 56
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 54
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 54
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 52
Endometrial carcinosarcoma 52
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 52
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 51
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 49
Newly diagnosed ovarian cancer: Which first-line treatment? 49
Clear cell carcinoma of the endometrium 48
PARP Inhibitors Resistance: Mechanisms and Perspectives 48
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 47
Recent progress in the use of pharmacotherapy for endometrial cancer 46
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 46
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 46
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 46
The role of artificial intelligence in managing multimorbidity and cancer 45
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 44
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 44
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 44
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 43
Advanced and recurrent endometrial cancer: State of the art and future perspectives 43
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 43
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 43
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 43
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 42
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 42
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 40
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 40
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 37
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 37
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 37
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 36
Management of stage III and IVa uterine cancer 36
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 36
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 36
Dostarlimab: From preclinical investigation to drug approval and future directions 34
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 34
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 34
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 34
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 31
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 30
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 29
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 29
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 27
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 27
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 26
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 25
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 23
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 22
Chemotherapy-free treatments: Are we ready for prime time? 22
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 22
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 21
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup 20
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 18
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 13
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 12
A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study 11
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial 9
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 5
Totale 4.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.160
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.160
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202082 0 0 0 0 0 0 0 0 0 0 32 50
2020/2021460 29 20 18 37 57 37 66 27 25 59 66 19
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/20251.318 35 40 121 61 97 59 86 74 206 229 310 0
Totale 4.945